drugset / Trial / NCT06484868
Open-label Study to Evaluate Metreleptin in Patients With Partial Lipodystrophy
NaSingle-groupOpen-labelTreatment
Summary
This is an Open Label, Phase IV, Post Authorisation Study to Evaluate the Efficacy, Safety and Immunogenicity of Daily Subcutaneous Metreleptin Treatment in people with Partial Lipodystrophy
Timeline
- Start
- 2024-02-08
- Primary completion
- 2028-02
- Completion
- 2028-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Metreleptin | Protein / enzyme biologic | — | Subcutaneous |